An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in…
VERDICT
The label
Accumulation
read at $40.01
Indivior Pharmaceuticals, Inc. holds its Accumulation at $40.01.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-31
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 19 days
Price
$40.01
Valuation
20.52 trailing · 9.60 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.15
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$40.01
20.52 P/E · 9.60 fwd
Our fair value
$59.00
48% discount
Analyst target (avg)
$50.00
+25% to current
Target low $46.00Analyst target rangeTarget high $59.00
▲ current $40.01 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$40.01
you are here
Conservative
$59.00
+47%
Analyst avg
$50.00
+25%
Our fair value
$59.00
+47%
Analyst high
$59.00
+47%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
19.20%
Profit margin
19.53%
Analyst consensus
Strong Buy · 6 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Addiction treatment at a bargain price
Opioid dependence keeps rising, yet Indivior sells the main buprenorphine medicines that help patients step away from heroin and painkillers. The business is expanding revenue 19 percent a year, turning 20 percent of sales into profit, and trades on a forward multiple of just 9.8 times earnings. Our fair-value estimate sits at 59 dollars against the current 40.54, giving a 46 percent margin of safety while the ethical screen flags the work as clearly useful.
Six analysts see a median target of 50 dollars, so the shares already look cheap on simple numbers. Unknown competitive defences and heavy reliance on one drug family keep the opportunity rating at none, which stops any stronger call. Currency moves, regulatory shifts on addiction medicines, and possible new entrants remain real threats to those margins.
The low multiple may simply reflect those gaps rather than a mispriced winner. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
INDV trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. Entered 2026-08-02 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-02Markup · changed$40.01+4.0%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
2026-07-18Accumulation$38.48+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
2026-07-03Accumulation$38.48+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$38.48Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$38.84
-2.2%
·
$978
-2.2%
2 months
$30.54
+24.4%
·
$1,244
+24.4%
3 months
$30.86
+23.1%
·
$1,231
+23.1%
6 months
$35.79
+6.2%
·
$1,062
+6.2%
1 year
$13.69
+177.6%
·
$2,776
+177.6%
2 years
$16.97
+123.9%
·
$2,239
+123.9%
3 years
$20.97
+81.2%
·
$1,812
+81.2%
5 years
$11.27
+237.3%
·
$3,373
+237.3%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever INDV does next, these words stay.
Indivior Pharmaceuticals, Inc. · INDV · Accumulation · $40.01
Recorded 2026-07-31 · before the outcome · scored mechanically
